Phase 1b trial of isatuximab, an anti-CD38 monoclonal antibody, in combination with carfilzomib as treatment of relapsed/refractory multiple myeloma.
Martin TG, Shah N, Richter J, Vesole DH, Wong SW, Huang CY, Madduri D, Jagannath S, Siegel DS, Biran N, Wolf JL, Parekh S, Cho HJ, Munster P, Richard S, Ziti-Ljajic S, Chari A.
Martin TG, et al. Among authors: huang cy.
Cancer. 2021 Jun 1;127(11):1816-1826. doi: 10.1002/cncr.33448. Epub 2021 Mar 18.
Cancer. 2021.
PMID: 33735504
Free PMC article.
Clinical Trial.